Navigation Links
Regeneron Named World's #1 Biopharmaceutical Employer in Science Magazine Annual Survey
Date:9/21/2012

TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #1 employer in the global biopharmaceutical industry in the journal's annual Top Employers Survey.

"This recognition by Science as the most respected company to work for in the biopharmaceutical industry is very satisfying for all of us at Regeneron," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals and George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer and President, Regeneron Laboratories.  "Since we opened our first lab in 1989, we have believed that innovative science could be harnessed to deliver important new medicines for serious conditions.  As we have grown from a handful of people to nearly 1,900 employees today, we have worked hard to maintain a culture that values rigorous science, creative thinking, and collegiality.  We are fortunate to have such talented employees who are dedicated to discovering and developing new treatments for patients in need."

This is the first year that Regeneron has captured the #1 position and the first time a New York based company has topped the survey.  Last year Regeneron was ranked #2.

The 2012 survey sought to identify the companies with the best reputations as employers, based on 4,276 survey responses from readers of Science and other survey invitees.  Survey participants came from North America (78%), Europe (14%), and Asia/Pacific Rim (5%); 93% worked in private industry.  Details of the rankings and survey results can be found in the September 21 online edition of Science and will be featured in the October 19, 2012 print issue.

On Monday, September 24, New York State Lt. Governor Robert Duffy and U.S. Congresswoman Nita Lowey and other public officials are scheduled to participate in an event with Regeneron's Tarrytown employees that will recognize this important achievement.

Separately, Regeneron announced another step to reinforce its commitment to science by launching a new Post-Doctoral Training Program that is accepting applications for its 2013 class.  The three-year multi-faceted program will integrate cutting edge science with didactic training, discussion groups, and focused mentoring.

About Regeneron Pharmaceuticals, Inc.  
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi.  Regeneron has filed a regulatory application with the U.S. Food and Drug Administration (FDA) for a second indication for EYLEA.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.

Contact Information:   
Peter Dworkin   
Corporate Communications  
914.847.7640  
peter.dworkin@regeneron.com

Manisha Narasimhan, Ph.D.  
Investor Relations    
914.847.5126    
manisha.narasimhan@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces September 2012 Investor Conference Presentations
2. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
3. Regeneron Announces June 2012 Investor Conference Presentations
4. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
5. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
6. Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
7. Donor Alliance Named Colorados Top Healthcare Company
8. Millennium Laboratories Angela Huskey Named Industry Pain Educator of the Year by American Society of Pain Educators
9. Impact Advisors Named to Inc. 5000 List of Nations Fastest-Growing Companies
10. Ingenuity Systems Named 2013 World Economic Forum Technology Pioneer
11. Saddleback Memorial Named First Robotic Training Epicenter for Gynecologic Surgery in Orange County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):